---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-191273"
form_type: "8-K/A"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-08-28T23:59:59+00:00"
generated_at: "2026-05-17T09:25:14.123604+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst settles FIRDAPSE patent suit with Lupin; generic entry delayed to Feb 2035

## Summary
- Lupin receives license to market generic FIRDAPSE no earlier than February 25, 2035, if FDA-approved.
- All pending patent litigation between Catalyst/SERB and Lupin will be terminated.
- Previous settlements reached with Teva Pharmaceuticals and Inventia Healthcare Limited.
- Ongoing FIRDAPSE patent litigation against Hetero remains active.
- Confidential settlement agreement to be submitted to FTC and DOJ for review.

## SEC filing metadata
- accession: 0001193125-25-191273
- form_type: 8-K/A
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-08-28T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525191273/0001193125-25-191273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525191273/d40349d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-191273
- JSON: https://secwatch.observer/filing/0001193125-25-191273.json
- Plain text: https://secwatch.observer/filing/0001193125-25-191273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.